-- Dr. Steffen Wagner appointed as new Chief Executive Officer and Andreas 
Stickler as new Chief Financial Officer

ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a specialty 
pharmaceutical company with a strategic focus on complex medicines in Europe, 
today announced several changes in senior leadership roles as it enters the 
next phase of its growth journey.

Photo - https://mma.prnewswire.com/media/1691859/Dr_Steffen_Wagner.jpg

Dr Steffen Wagner is to become the new Chief Executive Officer of ADVANZ 
PHARMA, starting early 2022. He succeeds Graeme Duncan, who will step down from 
his role and become a special advisor to the Board. Andreas Stickler will join 
from Merck Healthcare as the new Chief Financial Officer, succeeding Adeel 
Ahmad.

Dr Steffen Wagner is currently a member of the executive management team at 
STADA Arzneimittel AG and has been responsible for the company's European 
Markets division. Steffen is a medical doctor by training, has previously held 
senior roles with Biogen and within the Novartis Group, and worked as a 
consultant at McKinsey & Company and Bain & Company. He brings extensive 
international pharma experience that will be highly valuable in supporting 
ADVANZ PHARMA's continued journey. His predecessor, Graeme Duncan, has been 
with ADVANZ PHARMA since 2014 and has played a significant role in building the 
Company to date. He will continue working with the Board as a special advisor.

Andreas Stickler will join as the Company's new Chief Financial Officer in 
January 2022. Most recently, he has been CFO of Merck Healthcare, part of Merck 
KGaA, where he also served as Global Head of M&A and Business Development, 
driving major strategic acquisitions. He brings a wealth of global finance, 
healthcare and M&A expertise to the team. His predecessor, Adeel Ahmad, has 
been with the Company since 2013 and has helped deliver major transformation 
projects and built a sustainable business from which to grow.

These two key additions to the executive team of ADVANZ PHARMA are accompanied 
by several other senior leadership changes. On November 1, 2021, Susanna 
El-Armale joined as Chief Corporate Development Officer, following her prior 
role as Chief Corporate Development Officer of Theramex and succeeding former 
Chief Corporate Development Officer Guy Clark. Susanna brings broad experience 
spanning both M&A and BD activities and will be a central driver of the 
Company's active corporate development agenda. In January 2022, Chris Britten 
will join Susanna El-Armale's team as Senior Vice President for M&A, following 
his role as Head, M&A for Neuraxpharm. On October 11, Anke Niedernberg joined 
as Senior Vice President and Head of the Transformation Office. She brings a 
broad skillset to the leadership team, having spent time in private equity, 
consulting and running major change and growth projects for Sandoz for the last 
ten years.

These senior leadership changes build upon ADVANZ PHARMA's successful 2021 and 
will help fuel the Company's next phase of growth. In 2021, the Company 
delivered continued strong financial performance, succeeded in acquiring 
additional strategic assets, commenced the European launch of a generic version 
of Lanreotide and bolstered its organic pipeline with further in-licensing 
deals. ADVANZ PHARMA continues building towards achieving its corporate vision 
of becoming the "partner of choice" for complex specialty and hospital 
medicines in Europe.

About ADVANZ PHARMA
ADVANZ PHARMA is headquartered in London and has commercial affiliates in 
Europe, North America and Australia, and supply chain, regulatory and 
administrative operations in India. Furthermore, ADVANZ PHARMA has an 
established global network of commercial partners throughout the rest of the 
world. With an agile and experienced team, including direct sales, marketing, 
and medical capability across many of Europe's major markets, ADVANZ PHARMA 
supplies, innovates and enhances the critical medicines patients depend on, 
ensuring continued patient access and improving healthcare outcomes. ADVANZ 
PHARMA has a broad expertise in several therapeutic areas with strengths in the 
critical care, anti-infectives, endocrinology, cardiovascular and central 
nervous system therapeutic areas, along with direct sales access in Europe, 
making it an attractive partner when commercialising complex medicines, 
especially in the hospital channel. To find out more, please visit our website: 
https://www.advanzpharma.com.

Press contacts: Meral Nugent, Head of Communications, Tel: +44 7557 49 60 35, 
E-mail: meral.nugent@advanzpharma.com

SOURCE: ADVANZ PHARMA Corp.